Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Publications
The double-edged nature of antibody bivalency: mathematical and experimental analysis of cell surface antigen occupancy and opsonization
Journal article
Heirene L. et al, (2026), mAbs, 18
Image-based consensus molecular subtypes and colon cancer recurrence: Understanding the impact of lifestyle factors across subtypes of colon cancer
Journal article
Wesselink E. et al, (2026), Cancer Epidemiology, 103
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.
Journal article
Rampotas A. et al, (2026), Sci Transl Med, 18
Seminars
Chemical Approaches to Decoding Epigenetics
Thursday, 03 September 2026, 11am to 12pm
Speaker(s): Prof David Xiang
conference
